Actively Recruiting
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
Led by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Updated on 2024-10-01
1000
Participants Needed
6
Research Sites
228 weeks
Total Duration
On this page
Sponsors
C
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Lead Sponsor
I
Instituto de Salud Carlos III
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.
CONDITIONS
Official Title
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- No prior heart disease including significant structural heart changes or severe valve disease
- Adequate ultrasound window allowing visualization of most left ventricle segments
- Sinus rhythm with resting heart rate above 50 bpm
- Diabetes Mellitus type 2 patients with or without stable heart failure with normal ejection fraction
- Patients with cirrhosis classified by Child-Pugh scores A, B, or C with or without ascites
- Cancer patients receiving specified chemotherapy regimens including anthracyclines, trastuzumab, or sorafenib
- Expected survival over 6 months with first cancer diagnosis and ongoing specified treatment
- Control group without heart disease, diabetes, cancer, or liver disease
You will not qualify if you...
- Contraindications to esmolol such as severe bradycardia, atrioventricular block without pacemaker, cardiogenic shock, severe hypotension, decompensated heart failure, untreated pheochromocytoma, or acute asthma attack
- Beta-blocker use within 7 days before study
- History of arrhythmias preventing safe medication withdrawal
- Previous high-grade atrioventricular block without pacemaker
- Severe asthma with bronchial hyperresponsiveness
- Acute infection
- Participation in other clinical trials within 30 days before study
- Pregnancy or breastfeeding
- Inability to follow study protocol
- Diabetes types other than type 2
- Advanced heart failure (NYHA class IV)
- Oral beta-blocker treatment that cannot be safely stopped 72 hours before testing
- Active hepatitis B or C infection
- Previous cancer requiring systemic treatment (except certain skin or localized cancers)
- Prior systemic cancer treatment or thoracic radiotherapy exposure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, Spain, 08035
Actively Recruiting
2
Hospital Clínic de Barcelona
Barcelona, Barcelona, Spain, 08036
Not Yet Recruiting
3
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain, 28007
Actively Recruiting
4
Hospital Universitario La Paz
Madrid, Madrid, Spain, 28046
Actively Recruiting
5
Hospital Clínico Universitario de Salamanca
Salamanca, Salamanca, Spain, 37007
Actively Recruiting
6
Hospital Universitari i Politècnic La Fe
Valencia, Valencia, Spain, 46026
Not Yet Recruiting
Research Team
T
Tania Luis García, BS
CONTACT
P
Projects Department (CIBER)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here